CoChat
Sign Up
Cited by 192

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Lipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide

Gobbi, Marco, Re, Francesca, Canovi, Mara, Beeg, Marten, Gregori, Maria, Sesana, Silvia, Sonnino, Sandro, Brogioli, Doriano, Musicanti, Claudia, Gasco, Paolo, Salmona, Mario, Masserini, Massimo E.·2010·Biomaterials
DOI 10.1016/j.biomaterials.2010.04.044
Open this paper in CoChat — free account

Abstract

The neurotoxic beta-amyloid peptide (Abeta), formed in anomalous amounts in Alzheimer's disease (AD), is released as monomer and then undergoes aggregation forming oligomers, fibrils and plaques in diseased brains. Abeta aggregates are considered as possible targets for therapy and/or diagnosis of AD. Since nanoparticles (NPs) are promising vehicles for imaging probes and therapeutic agents, we realized and characterized two types of NPs (liposomes and solid lipid nanoparticles, 145 and 76 nm average size, respectively) functionalized to target Abeta(1-42) with high affinity. Preliminary immunostaining studies identified anionic phospholipids [phosphatidic acid (PA) and cardiolipin (CL)] as suitable Abeta(1-42) ligands. PA/CL-functionalized, but not plain, NPs interacted with Abeta(1-42) aggregates as indicated by ultracentrifugation experiments, in which binding reaction occurred in solution, and by Surface Plasmon Resonance (SPR) experiments, in which NPs flowed onto immobilized Abeta(1-42). All these experiments were carried out in buffered saline. SPR studies indicated that, when exposed on NPs surface, PA/CL display very high affinity for Abeta(1-42) fibrils (22-60 nm), likely because of the occurrence of multivalent interactions which markedly decrease the dissociation of PA/CL NPs from Abeta. Noteworthy, PA/CL NPs did not bind to bovine serum albumin. The PA/CL NPs described in this work are endowed with the highest affinity for Abeta so far reported. These characteris…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2010.04.044

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI
  2. Selkoe, 2001, Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein, J Alzheimers Dis, 3, 75, 10.3233/JAD-2001-3111 · DOI · Paper page
  3. Findeis, 2007, The role of amyloid beta peptide 42 in Alzheimer’s disease, Pharmacol Ther, 116, 266, 10.1016/j.pharmthera.2007.06.006 · DOI
  4. Nussbaum, 2003, Alzheimer’s disease and Parkinson’s disease, N Engl J Med, 348, 1356, 10.1056/NEJM2003ra020003 · DOI · Paper page
  5. Mann, 1996, Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer’s disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene, Am J Pathol, 148, 1257
  6. Lue, 1999, Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease, Am J Pathol, 155, 853, 10.1016/S0002-9440(10)65184-X · DOI · Paper page
  7. Crouch, 2008, Mechanisms of A beta mediated neurodegeneration in Alzheimer’s disease, Int J Biochem Cell Biol, 40, 181, 10.1016/j.biocel.2007.07.013 · DOI
  8. DeFelice, 2002, Beta-amyloid production, aggregation, clearance as targets for therapy in Alzheimer’s disease, Cell Mol Neurobiol, 22, 545, 10.1023/A:1021832302524 · DOI
  9. Greenberg, 2008, Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B, Ann Neurol, 64, 587, 10.1002/ana.21528 · DOI
  10. Look, 2007, Discovery of ADDL–targeting small molecule drugs for Alzheimer’s disease, Curr Alzheimer Res, 4, 562, 10.2174/156720507783018271 · DOI
  11. Matsuoka, 2003, Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid, J Neurosci, 23, 29, 10.1523/JNEUROSCI.23-01-00029.2003 · DOI
  12. Montet, 2006, Multivalent effects of RGD peptides obtained by nanoparticle display, J Med Chem, 49, 6087, 10.1021/jm060515m · DOI
  13. Hong, 2007, The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform, Chem Biol, 14, 107, 10.1016/j.chembiol.2006.11.015 · DOI
  14. Tassa, 2010, Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles, Bioconjugate Chem, 21, 14, 10.1021/bc900438a · DOI
  15. Matsuzaki, 2007, Physicochemical interactions of amyloid beta-peptide with lipid bilayers, Biochim Biophys Acta, 1768, 1935, 10.1016/j.bbamem.2007.02.009 · DOI
  16. Verdier, 2004, Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer’s disease, Curr Protein Pept Sci, 5, 19, 10.2174/1389203043486937 · DOI
  17. Chauhan, 2000, Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids, Neurochem Res, 25, 423, 10.1023/A:1007509608440 · DOI
  18. Cordy, 2006, The involvement of lipid rafts in Alzheimer’s disease, Mol Membr Biol, 23, 111, 10.1080/09687860500496417 · DOI · Paper page
  19. Taylor, 2007, Role of lipid rafts in the processing of the pathogenic prion and Alzheimer’s amyloid-beta proteins, Semin Cell Dev Biol, 18, 638, 10.1016/j.semcdb.2007.07.008 · DOI
  20. Kakio, 2002, Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid, Biochemistry, 41, 7385, 10.1021/bi0255874 · DOI
  21. Lin, 2007, Kinetics and enthalpy measurements of interaction between beta- amyloid and liposomes by surface plasmon resonance and isothermal titration microcalorimetry, Colloids Surf B Biointerfaces, 58, 231, 10.1016/j.colsurfb.2007.03.014 · DOI
  22. Ariga, 2001, Characterization of high-affinity binding between gangliosides and amyloid beta-protein, Arch Biochem Biophys, 388, 225, 10.1006/abbi.2001.2304 · DOI
  23. Taniguchi, 2009, “Click peptide”: pH-triggered in situ production and aggregation of monomer Abeta1-42, Chembiochem, 10, 710, 10.1002/cbic.200800765 · DOI
  24. Bulbarelli, 2009, TrkA pathway activation induced by amyloid-beta (Abeta), Mol Cell Neurosci, 40, 365, 10.1016/j.mcn.2008.12.006 · DOI
  25. Wu, 1988, Quantification of gangliotetraose gangliosides with cholera toxin, Anal Biochem, 173, 368, 10.1016/0003-2697(88)90201-1 · DOI
  26. Bartlett, 1959, Phosphorus assay in column chromatography, J Biol Chem, 234, 466, 10.1016/S0021-9258(18)70226-3 · DOI
  27. Svennerholm, 1957, Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method, Biochim Biophys Acta, 24, 604, 10.1016/0006-3002(57)90254-8 · DOI
  28. Palestini, 2002, Developmental changes in the protein composition of sphingolipid- and cholesterol-enriched membrane domains of rat cerebellar granule cells, J Neurosci Res, 67, 729, 10.1002/jnr.10170 · DOI
  29. Zhang, 2001, Interaction of cationic antimicrobial peptides with model membranes, J Biol Chem, 276, 35714, 10.1074/jbc.M104925200 · DOI
  30. Bravman, 2006, Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor, Anal Biochem, 358, 281, 10.1016/j.ab.2006.08.005 · DOI
  31. Re, 2008, Prion protein structure is affected by pH-dependent interaction with membranes: a study in a model system, FEBS Lett, 582, 215, 10.1016/j.febslet.2007.12.003 · DOI
  32. Sesana, 2008, Membrane features and activity of GPI-anchored enzymes: alkaline phosphatase reconstituted in model membranes, Biochemistry, 47, 5433, 10.1021/bi800005s · DOI
  33. Roney, 2005, Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease, J Controlled Release, 108, 193, 10.1016/j.jconrel.2005.07.024 · DOI
  34. Schwendener, 2007, Liposomes in biology and medicine, Adv Exp Med Biol, 620, 117, 10.1007/978-0-387-76713-0_9 · DOI
  35. Uner, 2007, Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives, Int J Nanomedicine, 2, 289
  36. Webb, 1995, Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models, Br J Cancer, 72, 896, 10.1038/bjc.1995.430 · DOI
  37. Boehlke, 2006, Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug, Expert Opin Biol Ther, 6, 409, 10.1517/14712598.6.4.409 · DOI
  38. Gelmon, 1999, Phase I study of liposomal vincristine, J Clin Oncol, 17, 697, 10.1200/JCO.1999.17.2.697 · DOI
  39. Thomas, 2006, Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia, Cancer, 106, 120, 10.1002/cncr.21595 · DOI
  40. Choucair, 2007, Preferential accumulation of Abeta(1-42) on gel phase domains of lipid bilayers: an AFM and fluorescence study, Biochim Biophys Acta, 1768, 146, 10.1016/j.bbamem.2006.09.005 · DOI
  41. Qiu, 2009, Cholesterol modulates the interaction of beta-amyloid peptide with lipid bilayers, Biophys J, 96, 4299, 10.1016/j.bpj.2009.02.036 · DOI
  42. Serpe, 2006, Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines, J Nanosci Nanotechnol, 6, 3062, 10.1166/jnn.2006.423 · DOI
  43. Podio, 2000, Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats, J Pharm Pharmacol, 52, 1057, 10.1211/0022357001774976 · DOI
  44. Zara, 2002, Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues, J Drug Target, 10, 327, 10.1080/10611860290031868 · DOI
  45. Gardberg, 2007, Molecular basis for passive immunotherapy of Alzheimer’s disease, Proc Natl Acad Sci USA, 104, 15659, 10.1073/pnas.0705888104 · DOI
  46. Kingsley, 2006, Nanotechnology: a focus on nanoparticles as a drug delivery system, J Neuroimmune Pharmacol, 1, 340, 10.1007/s11481-006-9032-4 · DOI
  47. Houtkooper, 2008, Cardiolipin, the heart of mitochondrial metabolism, Cell Mol Life Sci, 65, 2493, 10.1007/s00018-008-8030-5 · DOI
  48. Gascard, 1991, Asymmetric distribution of phosphoinositides and phosphatidic acid in the human erythrocyte membrane, Biochim Biophys Acta, 1069, 27, 10.1016/0005-2736(91)90100-M · DOI
  49. Zhang, 2009, Metabolite identification and profiling in drug design: current practice and future directions, Curr Pharm Des, 15, 2220, 10.2174/138161209788682460 · DOI

Cited by

Sorted by citations

Metadata

Authors
Gobbi, M., Re, F., Canovi, M., Beeg, M., Gregori, M., Sesana, S., Sonnino, S., Brogioli, D., Musicanti, C., Gasco, P., Salmona, M., & Masserini, M. E.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2010-09
Volume
31
Issue
25
Pages
6519-6529
ISSN
0142-9612
DOI
10.1016/j.biomaterials.2010.04.044
Cited by
192
References
8
Language
en
Licence
Funders
European Community’s Seventh Framework Programme (FP7/2007–2013, 212043)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review